What it is
Glutathione is the endogenous tripeptide γ-L-glutamyl-L-cysteinyl-glycine (C₁₀H₁₇N₃O₆S, 307.32 Da, CAS 70-18-8, PubChem CID 124886). It is synthesized in the cytoplasm of nearly every mammalian cell in two ATP-dependent steps: γ-glutamylcysteine ligase (GCL, formerly γ-GCS) condenses glutamate and cysteine (the rate-limiting step, feedback-inhibited by GSH), and glutathione synthetase adds glycine. The unusual γ-peptide bond between glutamate's side-chain γ-carboxyl and cysteine's α-amino group resists most peptidases — only γ-glutamyltransferase (GGT) can cleave it — which is why exogenous GSH is efficiently hydrolyzed on the gut brush border and on the vascular endothelium. Intracellular concentrations reach 0.5–10 mM (>90% reduced form in healthy tissue), establishing GSH as the single largest non-protein thiol pool in the body. It is not a 'peptide therapeutic' — it is a ubiquitous metabolite, which makes the evidence framing fundamentally different from exogenous peptides like BPC-157 or semaglutide.
In plain English
Glutathione is a tiny chain of three amino acids (glutamate, cysteine, and glycine) that almost every one of your cells makes on its own using two energy-powered steps. It has an unusual chemical bond that keeps most enzymes from breaking it down — except one specific enzyme (GGT) that lives in the gut wall and on blood-vessel linings. That is the main reason swallowed glutathione mostly gets chewed up before it reaches the bloodstream. Inside cells, glutathione is the most common sulfur-containing molecule by far — millions of times more concentrated than any supplement dose could add. It is not a peptide drug the way BPC-157 or semaglutide are drugs. It is a natural chemical your body is already flooded with.
How it works
- 01
Glutathione peroxidase (GPx) — primary peroxide defense
Glutathione peroxidases are selenoprotein enzymes that reduce hydrogen peroxide and lipid hydroperoxides using GSH as the two-electron donor: 2 GSH + H₂O₂ → GSSG + 2 H₂O. GPx1 (cytosolic) and GPx4 (membrane-associated, lipid-peroxide-specific) are the dominant forms; GPx4 knockout is embryonic lethal and its activity is the gatekeeper of ferroptosis. Mitochondria lack catalase, so mitochondrial GSH + GPx is the sole enzymatic defense against matrix-generated H₂O₂ (Marí 2020, Antioxidants; Lu 2013, Mol Aspects Med). Resulting GSSG is reduced back to GSH by glutathione reductase using NADPH — the redox cycle that couples GSH metabolism to the pentose phosphate pathway.
In plain English
It is the body's main way of neutralizing hydrogen peroxide
Your cells constantly generate small amounts of hydrogen peroxide (the same chemical as the brown-bottle drugstore liquid, but at tiny concentrations). Enzymes called glutathione peroxidases use glutathione to safely neutralize that peroxide into water. Mitochondria (the cells' power plants) rely on this system completely — they don't have the backup enzyme most cells have. After doing its job, the used-up glutathione gets recycled by another enzyme using a different cell chemical called NADPH.
- 02
Glutathione S-transferase (GST) — Phase II detoxification
The cytosolic GST superfamily (α, μ, π, θ, ζ classes in humans) catalyzes nucleophilic attack of the GSH thiolate on electrophilic xenobiotics and reactive endogenous metabolites (α,β-unsaturated aldehydes, quinones, epoxides), forming GSH conjugates that are exported via MRP1/MRP2 transporters and processed through the mercapturic-acid pathway (GGT → dipeptidase → N-acetyltransferase) for renal elimination (Hayes 2005, Annu Rev Pharmacol Toxicol). This is the biochemist's 'detoxification' — hepatocyte-localized conjugation, not the infusion-clinic marketing term.
In plain English
It tags toxins so the body can flush them out
When the liver encounters a harmful chemical (from food, drugs, or internal metabolism), a family of enzymes sticks glutathione onto it. That tag makes the bad chemical water-soluble so it can be pumped out of the cell and peed out through the kidneys. This is what biochemists actually mean by "detox." It is a specific liver-cell process — very different from the vague "flushing toxins" language used in IV drip marketing.
- 03
Cysteine reservoir and the rate-limiting role of cysteine
De novo GSH synthesis is rate-limited by intracellular cysteine, not glycine or glutamate. Cysteine is the scarce, autoxidation-prone input; this is why NAC (N-acetylcysteine) rescues hepatic GSH in acetaminophen overdose and why GlyNAC (glycine + NAC) supplementation (Sekhar 2023, Nutrients; Kumar 2023, J Gerontol) reliably raises erythrocyte GSH in deficient elderly adults. Oral GSH is less efficient than oral cysteine precursors because most ingested GSH is hydrolyzed at the brush border before reaching the portal circulation (Witschi 1992, Eur J Clin Pharmacol).
In plain English
The bottleneck is cysteine — so cysteine building blocks often work better than glutathione itself
Of the three amino acids in glutathione, cysteine is the one in shortest supply and the hardest to come by from food. That is why NAC (a stable form of cysteine) works for Tylenol overdose, and why studies of GlyNAC (glycine + NAC) reliably raise glutathione in older people — you're feeding the bottleneck directly. Taking glutathione by mouth is less efficient because most of it gets chewed up in the gut before it reaches the bloodstream.
- 04
Protein S-glutathionylation — redox signaling
Reversible formation of mixed disulfides between GSH and protein cysteine residues (Protein-SSG) is now recognized as a major redox post-translational modification, regulating metabolic enzymes (GAPDH, pyruvate kinase), signaling proteins (PTP1B, NF-κB), and apoptotic caspases (Mailloux 2024, Redox Biol). Glutaredoxins (Grx1/Grx2) and sulfiredoxin catalyze deglutathionylation. This positions GSH not just as an antioxidant buffer but as a signaling cofactor — and complicates the 'more GSH is better' intuition that drives consumer marketing.
In plain English
It is also a signaling molecule — not just a "more is better" antioxidant
Glutathione doesn't only soak up damage — it also attaches itself to specific spots on proteins to turn them on and off. Through this, it helps control how cells use energy, how inflammation turns on, and even when cells decide to die. Because glutathione is doing active signaling work, the marketing slogan "more is better" is probably too simple. Too much could disrupt signals the body is trying to send.
- 05
Pharmacokinetics of exogenous GSH — why route matters
Oral GSH: Witschi (1992) administered 3 g oral GSH to 7 healthy volunteers and observed no significant rise in plasma GSH, concluding oral bioavailability is effectively zero; more recent analogue and liposomal work (Richie 2015; the 2025 N-methylated analogue work in MDPI Pharmaceutics) has tried to circumvent brush-border GGT hydrolysis with mixed results. IV GSH: Aebi (1991, Eur J Clin Pharmacol) administered 2 g IV to 5 volunteers and showed plasma GSH cleared with a half-life of ~10 minutes; total GSH disappears from the circulation within ~90 minutes. Intranasal: Mischley (2013) showed modest brain GSH increase on MRS, the basis of the Mischley 2015 PD trial. The short plasma half-life is the mechanistic argument against IV 'detox drips': a bolus that clears in 10 minutes does not meaningfully raise hepatocyte intracellular GSH.
In plain English
How it's given matters a lot — most routes don't work well
Oral glutathione: A 1992 study gave 7 healthy people 3 grams by mouth. It barely raised blood glutathione at all — the gut breaks it down. Liposomal and chemically modified versions have tried to get around this with mixed success. IV glutathione: A 1991 study gave 5 people 2 grams by IV. It was cleared from the blood in about 10 minutes, and was completely gone in about 90 minutes. Nasal spray: A 2013 study showed a small increase in brain glutathione — the reason for the later Parkinson's nasal-spray trial. The 10-minute half-life is the main biochemistry reason the "IV detox drip" claims don't hold up — the drug is gone before it could do any real work inside liver cells.
- 06
Proposed skin-whitening mechanism (and why it does not justify IV use)
In-vitro work (Villarama 2005; del Rosario-Blasco 2008) shows that GSH at millimolar concentrations in melanocyte culture shifts tyrosinase product distribution away from eumelanin toward lighter pheomelanin, and that GSH inhibits tyrosinase activity. Translating this to systemic IV dosing requires that a plasma GSH spike reaches melanocyte intracellular pools at the required concentration for long enough to matter — a chain of assumptions not supported by the pharmacokinetic data above. The controlled oral trials (Arjinpathana 2012; Weschawalit 2017; Handog 2016) show small and inconsistent melanin-index changes that do not translate reliably to patient-reported outcomes.
In plain English
The skin-lightening story works in a dish, but the human evidence is weak
In lab dishes, lots of glutathione makes pigment cells produce a lighter type of melanin instead of darker melanin, and slows down the enzyme (tyrosinase) that builds pigment. But jumping from that to "IV drips whiten skin" requires that the drug actually reach the inside of pigment cells at high enough levels for long enough — and the 10-minute blood half-life says it doesn't. The small, controlled oral trials show tiny, inconsistent changes on pigment meters that don't reliably match what patients actually notice in the mirror.